Merck boosts infectious disease assets in $3.7bn Idenix purchase
Beating out other rumored bidders including AbbVie Inc. and Johnson & Johnson, Merck & Co. Inc. paid $24.50 per share (a 264% premium), or $3.7bn total, to buy publicly traded Idenix Pharmaceuticals Inc. (viral diseases). At just over $4bn in sales last year, Merck’s infectious disease portfolio (not including vaccines) made up 11% of the company’s pharma sales. Idenix may improve that number, although the first drug to come out of the acquisition is years away at the least.
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.